Sciele Pharma, Inc. - Statement of Ownership: Solicitation (SC 14D9)

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

---

 

SCHEDULE 14D-9

(Rule 14d-101)

 

Solicitation/Recommendation Statement Under
Section 14(d)(4) of the Securities Exchange Act of 1934

 

---

 

SCIELE PHARMA, INC.

(Name of Subject Company)

 

SCIELE PHARMA, INC.

(Name of Person(s) Filing Statement)

 

Common Stock, $0.001 par value per share

(Title or Class of Securities)

 

808627103

(CUSIP Number of Class of Securities)

 

---

 

Patrick P. Fourteau
Chief Executive Officer
Sciele Pharma, Inc.
5 Concourse Parkway, Suite 1800
Atlanta, Georgia 30328
[phone]

 (Name, address and telephone number of person authorized
to receive notices and communications on behalf of the person(s) filing statement)

 

---

 

With Copies to:

 

W. Tinley Anderson, III, Esq.
Paul, Hastings, Janofsky & Walker LLP
600 Peachtree St., N. E., Suite 2400
Atlanta, GA 30308
[phone]

 

x                                   Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

 

 

 

---

 

This Schedule 14D-9 contains the following exhibits:

 

Exhibit A – Exhibit A is a joint press release, dated September 1, 2008, relating to the proposed acquisition of Sciele Pharma, Inc. by Shionogi & Co., Ltd.

 

Exhibit B – Exhibit B is a script of a presentation to analysts made on September 2, 2008.

 

1

---